Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 22,468 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at $1,258,340.40. This represents a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Ian Mortimer also recently made the following trade(s):
- On Monday, January 27th, Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50.
Xenon Pharmaceuticals Price Performance
Shares of Xenon Pharmaceuticals stock traded up $0.16 during trading on Monday, reaching $40.11. 290,667 shares of the stock traded hands, compared to its average volume of 383,885. Xenon Pharmaceuticals Inc. has a 52-week low of $35.53 and a 52-week high of $50.99. The business has a fifty day simple moving average of $40.20 and a two-hundred day simple moving average of $40.82. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of -14.22 and a beta of 1.20.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the previous year, the firm posted ($0.73) EPS. On average, research analysts predict that Xenon Pharmaceuticals Inc. will post -3.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Xenon Pharmaceuticals
Several large investors have recently bought and sold shares of the business. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 641 shares in the last quarter. Avior Wealth Management LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $101,000. nVerses Capital LLC purchased a new position in Xenon Pharmaceuticals in the third quarter worth about $102,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock worth $106,000 after acquiring an additional 487 shares during the last quarter. Finally, KBC Group NV increased its stake in Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 780 shares during the last quarter. Institutional investors own 95.45% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on XENE shares. HC Wainwright restated a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Raymond James reissued an "outperform" rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $56.00.
Get Our Latest Stock Report on XENE
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
